Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation - A compassionate use experience

Bone Marrow Transplantation

Volumn 25, Issue 2, 2000, Pages 161-165

  DeVincenzo, J P ^a,b   Hirsch, R L ^c   Fuentes, R J ^c   Top Jr , F H ^c  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b LE BONHEUR CHILDREN S HOSPITAL   (United States)

^c MEDIMMUNE   (United States)

Author keywords

Bone marrow transplantation; Immune globulin; Palivizumab; Respiratory syncytial virus; Ribavirin; Treatment

Indexed keywords

ANTIVIRUS AGENT; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RIBAVIRIN;

ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; COUGHING; FEVER; HUMAN; INFANT; LOWER RESPIRATORY TRACT INFECTION; NEUROPATHY; PERICARDIAL EFFUSION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TACHYCARDIA; TACHYPNEA; VISUAL IMPAIRMENT;

EID: 0033974940     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702118     Document Type: Article

References (31)

1. Mangi MH. Outbreak of respiratory syncytial virus (RSV) infection in adult bone marrow transplant unit (BMT): role of ribavirin treatment and recommendations for prevention of RSV infection in high risk patients. Blood 1998: 92: 10 (Suppl. 1), Abstr. 4441.
2. Whimbey E, Champlin RE, Couch RB et al. Community respiratory virus infections among hospitalized adult hone marrow transplant recipients. Clin Infect Dis 1996; 22: 778-782.
3. Harrington RD, Hooton TM, Hackman RC et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis 1992; 165: 987-993.
4. Martin MA, Bock JM, Pfaller MA, Wenzel RP. Respiratory syncytial virus infections in adult bone marrow transplant recipients. Lancet 1988; 1: 1396-1397.
5. Ljungman P, Gleaves CA, Meyers JD. Respiratory virus infection in immunocompromised patients. Bone Marrow Transplant 1989; 4: 35-40.
6. Sica S, Leone G, Marra R et al. Respiratory syncytial virus infection in bone marrow transplantation: a case report. Haematologica 1990; 75: 184-186.
7. Takimoto CH, Cram DL, Root RK. Respiratory syncytial virus infections on an adult medical ward. Arch Intern Med 1991; 151: 706-708.
8. Englund JA, Anderson LJ, Rhame RS. Nosocomial transmission of respiratory syncytial virus in immunocompromised adults. J Clin Microbiol 1991; 29: 115-119.
9. Fouillard L, Mouthon L, Laporte JP et al. Severe respiratory syncytial virus pneumonia after autologous bone marrow transplantation: a report of three cases and review. Bone Marrow Transplant 1992; 9: 97-100.
10. Win N, Mitchell D, Pugh S, Russell NH. Successful therapy with ribavirin of late onset respiratory syncytial virus pneumonitis complicating allogeneic bone marrow transplantation. Clin Lab Haemat 1992; 14: 29-32.
11. Whimbey E, Champlin RE, Englund JA et al. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant 1995; 16: 393-399.
12. Hertz MI, Englund JA, Snover D et al. Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: a clinical approach and review of the literature. Medicine 1989; 68: 269-281.
13. Englund JA, Sullivan CJ, Jordan MC et al. Respiratory syncytial virus infection in immunocompromised adults. Ann Int Med 1988; 109: 203-208.
14. Bowden RA. Respiratory virus infections after marrow transplant: the Fred Hutchinson Cancer Research Center experience. Am J Med 1997; 102: 27-30.
15. Physician's Desk Reference, 52 edn. Medical Economics Company: Montvale, NJ, 1998.
16. Prince GA, Hemming VG, Horswood RL, Channock RM. Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat. Virus Res 1985; 3: 193-206.
17. Prince GA, Hemming VG, Horswood RL et al. Mechanism of antibody-mediated viral clearance in immunotherapy of respiratory syncytial virus infection in cotton rats. J Virol 1990; 64: 3091-3092.
18. Hemming VG, Prince GA, Horswood RL et al. Studies of passive immunotherapy for infections of respiratory syncytial virus in the respiratory tract of a primate model. J Infect Dis 1985; 152: 1083-1087.
19. Ottolini MG, Prince GA, Darnell MR et al. Immunoprophylaxis and immunotherapy are effective against respiratory syncytial virus infection in immunosuppressed cotton rats. Pediatr Res 1993; 33: 178A Abstr. 1048.
20. Wyde PR, Wilson SZ, Petrella R, Gilbert BE. Efficacy of high dose-short duration ribavirin aerosol in the treatment of respiratory syncytial virus infected cotton rats and influenza B virus infected mice. Antiviral Res 1987; 7: 211-220.
21. Gruber WC, Wilson SZ, Throop BJ, Wyde PR. Immunoglobulin administration and ribavirin therapy: efficacy in respiratory syncytial virus infection of the cotton rat. Pediatr Res 1987; 21: 270-274.
22. DeVincenzo JP, Leombruno D, Soiffer RJ, Siber GR. Immunotherapy of respiratory syncytial virus pneumonia following bone marrow transplantation. Bone Marrow Transplant 1996; 17: 1051-1056.
23. Siber GR, Leombruno D, Leszczynski J et al. Comparison of antibody concentrations and protective activity of a respiratory syncytial virus immune globulin and conventional immune globulin. J Infect Dis 1994; 169: 1368-1373.
24. Buckingham SC, Bush A, DeVincenzo JP. Nasal respiratory syncytial virus quantity correlates with disease severity in hospitalized infants. Clin Infect Dis 1998; 27: 977 (Abstr. 299).
25. Rodriguez, WJ, Gruber WC, Groothuis JR et al. Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children. Pediatrics 1997; 100: 937-942.
26. Rodriguez WJ, Gruber WC, Welliver RC et al. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group (see comments). Pediatrics 1997; 99: 454-461.
27. American Academy of Pediatrics-Committee on Infectious Diseases. Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. Pediatrics 1996; 97: 137-139.
28. Johnson S, Oliver C, Prince GA et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997; 176: 1215-1224.
29. Impact Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high risk infants. Pediatrics 1998; 102: 531-537.
30. Malley R, DeVincenzo J, Ramilo O et al. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis 1998; 178: 1555-1561.
31. Jones BL, Clark S, Curran ET et al. Control of respiratory syncytial virus infection in immunocompromised adults. Presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 24-27, 1998, San Diego, CA. Abstr. K-43.